- Home
- FTH vs AYTU Comparison
FTH vs AYTU Comparison
Compare FTH & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FTH | AYTU |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.9M | 27.4M |
| IPO Year | 2021 | 2015 |
Fundamental Metrics
Financial Performance| Metric | FTH | AYTU |
|---|---|---|
| Price | $26.00 | $2.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.33 |
| AVG Volume (30 Days) | ★ 112.0K | 28.4K |
| Earning Date | N/A | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,632,080.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $43.75 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 277.47 |
| 52 Week Low | $17.50 | $1.65 |
| 52 Week High | $28.98 | $3.07 |
Technical Indicators
Market Signals| Indicator | FTH | AYTU |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 48.07 |
| Support Level | N/A | $2.20 |
| Resistance Level | N/A | $2.32 |
| Average True Range (ATR) | 0.00 | 0.11 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 0.00 | 48.15 |
Price Performance
Historical ComparisonAbout AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.